A Clinical Study Testing How Well the Medical Device HTIC (a Type of Animal-derived Collagen) Works in Treating Skin Problems, Such as Scars, Loss of Firmness, and Volume in Certain Areas of the Face and Body

NCT07153393 | Completed

• 1 other identifier: HTIC-10-22
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial aims to evaluate the efficacy of the experimental medical device HTIC, which contains Type I collagen of animal origin, in treating skin defects such as scars, loss of tone, and volume in certain areas of the face and body. HTIC is administered through an injection technique applied under the skin. The main research question is: "Is it possible to achieve clinical improvement of skin defects through the use of the experimental device HTIC?" Additionally, the study has the following secondary objectives:

• To assess any discomfort experienced during administration;
• To evaluate the subject's level of satisfaction following the entire treatment;
• To assess the safety and tolerability of the experimental device HTIC. HTIC is a sterile powder composed solely of animal-derived collagen (heterologous bovine Type I collagen, allergen-free and compliant with current regulations), packaged in 10 ml glass vials. Each vial contains 100 mg of sterile bovine Type I collagen powder. The trial will be conducted at a single site in Italy, specifically at the Federico II University Hospital. A total of 45 subjects will participate in the study.

Conditions

Skin Aging of Face and Hands; Cicatrix; Scars; Atrophic Scar

Outcome Measures

Primary Outcomes (1)

• Measurement of the global aesthetic change between Visit 0 (Screening and Baseline) and Visit 5 (7 days) after the last HTIC injection

  The aesthetic change will be assessed by the Investigator using a 5-point Global Aesthetic Improvement Scale (GAIS) by comparing the subject's photograph taken prior and after the treatment. (Scale values: from 1 to 5.) Lower scores indicate a better outcome (greater aesthetic improvement), while higher scores indicate a worse outcome (no improvement or worsening).

  Screening and Baseline visit (day 0) and Visit 5 ( 7 days after the last HTIC injection_Visit 4)

Secondary Outcomes (4)

• Clinical skin assessment together with photographic evaluation at Visit 0 and Visit 5, using the 7-point Modified Fitzpatrick Wrinkle Scale (MFWS).

  Screening and Baseline visit (day 0) and visit 5 (7 days after the last HTIC injection_V4)

• Self-assessment of the subject's satisfaction with the procedure using a Visual Analog Scale (VAS), ranging from 0 (very satisfied) to 10 (very dissatisfied), at Visit 5 compared to Visit 1

  Visit 5 (7 days from the last HTIC injection) and Visit 1(≤7 days from Screening & baseline visit_day 0)

• Self-assessment of pain by the subject during the injection treatment at Visits 1, 2, 3, and 4, using a Visual Analog Scale (VAS) after each treatment

  At visit 1(≤7 days from Screening & Baseline visit_day 0), Visit 2 (7 days from V1), Visit 3(7 days from V2) and Visit 4 (7 days from V3)

• Collection and evaluation of the rate of related adverse events (AEs) occurring during the study.

  at Screening & Baseline visit (day 0), Visit 1(≤7 days from V0), Visit 2 (7 days from V1), Visit 3 (7 days from V2), Visit 4 (7 days from V3) and Visit 5 (7 days from V4_the last HTIC injection)

Study Arms (1)

HTIC - Adults 18-50, Fitzpatrick I-V, Mild to Moderate Skin Volume Loss

EXPERIMENTAL

In this arm, 45 subjects of both sexes, aged between 18 and 50 years, of Caucasian ethnicity with Fitzpatrick skin phototype ranging from I to V, will receive treatment with the experimental medical device HTIC. Participants will be selected based on the presence of skin defects characterized by mild to moderate volume loss due to acne scars, other skin lesions, or photoaging. Inclusion requires a minimum score of 2 according to the Modified Fitzpatrick Wrinkle Scale. The treatment involves subcutaneous administration of HTIC, consisting of injecting 0.1 ml per intradermal site at intervals of approximately 2 cm.

Device: Type I Bovine Collagen (HTIC)

Interventions

Type I Bovine Collagen (HTIC) DEVICE

HTIC is a sterile collagen powder (100 mg) contained in a glass vial, which is diluted by adding 5 ml of saline solution (0.9% sodium chloride solution) to obtain a suspension. This suspension will be prepared immediately before treatment. The procedure consists of performing a few microinjections of the product (0.1 ml per injection) into the dermis at intervals of approximately 2 cm, using a very fine needle (30G/32G, 4 mm) in the areas to be treated (face, neck, décolleté, and hands).

HTIC - Adults 18-50, Fitzpatrick I-V, Mild to Moderate Skin Volume Loss

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Adult subjects (age between 18-50 years).
• Subjects in good health.
• Subjects that presented skin atrophy from acne scarring, other injury, or photo-aging (from mild to moderate).
• Subjects with a score at least 2 according to the Modified Fitzpatrick Wrinkle Scale (MFWS).
• The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Ethics Committee (EC).

You may not qualify if:

• Pregnant or breastfeeding.
• Subjects that had undergone other medical invasive aesthetic treatments for the last 18 months before the enrolment.
• Subjects with acne.
• Subjects with seborrheic skin.
• Subjects with normotonic, normoelastic, and normotrophic skin.
• Subjects with autoimmune connective tissue disorders (connectivopathies).
• Subjects with a tendency to develop hypertrophic or keloid scars.
• Subjects undergoing immunosuppressive therapy.
• Any cutaneous pathology of infectious, inflammatory, viral and vascular type affecting the treated area.
• History of allergy or hypersensitivity to any component of the study devices.
• Performing permanent filler in the past.
• Use of any therapeutic agent for photoaging or skin rejuvenation within 15 days from the enrolment.
• Smoking.
• Wound healing disorders.
• Participation in other clinical studies.

Sponsors & Collaborators

• Centro Studi Dermatologici S.r.l.: lead

Study Sites (1)

Azienda Ospedaliera Federico II

Napoli, Italy

Location

MeSH Terms

Conditions

Cicatrix

Condition Hierarchy (Ancestors)

Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 22, 2025
• First Posted: September 4, 2025
• Study Start: January 30, 2025
• Primary Completion: May 27, 2025
• Study Completion: May 27, 2025
• Last Updated: September 4, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

IT (1)